CRBP Corbus Pharmaceuticals Holdings
$3.99▼ -1.48%
Healthcare
Other
Pre-market
$4.06▲ +1.75%
Oct 27, 7:15 AM ET
Volume 847.3K
Avg Volume (10D) 818.6K
Key Metrics & Fundamentals
Market Cap
$77.17M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.87 - 18.11
% vs 50 MA
-47.81%
% vs 200 MA
-54.13%
RSI-14
18.3
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.27
Free Cash Flow
-$29.63M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$36.14M
COGS
–
Operating Exp
$36.19M
Operating Income
-$36.19M
EBIT
-$36.19M
Pretax Income
-$35.04M
Net Income
-$35.04M
EPS (Diluted)
-1.81
Price & Volume History
Loading chart…
Recent News
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
GlobeNewswire · Sep 29, 2026 8:00 AM ET
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Zacks · Sep 17, 2026 9:00 AM ET
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
MarketBeat · Sep 15, 2026 4:02 AM ET
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
InvestorsHub · Sep 14, 2026 9:28 AM ET
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
GlobeNewswire · Sep 14, 2026 7:00 AM ET
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
GlobeNewswire · Sep 11, 2026 4:01 PM ET
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 17, 2026 10:00 AM ET
Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
MT Newswires · Aug 13, 2026 5:22 AM ET
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating
MT Newswires · Aug 7, 2026 9:18 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CRBP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.